SELECT * FROM `stock_list` WHERE `symbol` = "IMUX" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1 SELECT * FROM `stock_list` where symbol='IMUX' AND exchange = 'NAS' limit 0,1 SELECT * FROM `stock_list` WHERE `symbol` = "IMUX" and stock_list.exchange IN (SELECT exchange FROM gurufocu_main.stock_list_exchanges where country='USA' and active=1) limit 0,1
IMUX (Immunic) Interest Coverage
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Immunic's
Operating Income
for the
three
months ended in Dec. 2023 was $-23.38 Mil. Immunic's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil.
GuruFocus does not calculate 's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Immunic Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Immunic's Interest Coverage or its related term are showing as below:
IMUX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 114.62 * Ranked among companies with meaningful Interest Coverage only.
The historical data trend for Immunic's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Immunic's Interest Coverage
For the Biotechnology subindustry, Immunic's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunic's Interest Coverage Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunic's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Immunic's Interest Coverage falls into.
Immunic Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
GuruFocus does not calculate Immunic's interest coverage with the available data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Immunic Interest Coverage Related Terms
Thank you for viewing the detailed overview of Immunic's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IMUX has been successfully added to your 